Pancreatic Cancer Research

ResearcherMoffitt Cancer CenterActive in the last 2 years

Danielle K. DePeralta

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5990-0124; OpenAlex author ID A5077625963. Sources: OpenAlex.

Their work

Papers
18 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
36
Papers, trials and grants by year

2020: 2 papers · 2021: 1 paper · 2022: 2 papers · 2023: none · 2024: 6 papers · 2025: 5 papers · 2026: 2 papers

Papers 18

  1. Medicaid Expansion Timing and Pancreatic Cancer Resection Rates and Survival. Co-author DOI 10.1001/jamasurg.2026.0057↗
  2. Survival Disparities in Early-Onset Pancreatic Cancer (EOPC): The Role of Socioeconomic Status and Healthcare Access. Co-author DOI 10.1002/jso.70148↗
  3. Evaluating the Association of Area Deprivation Index (ADI) on Postoperative Outcomes in Pancreatic Adenocarcinoma. Co-author DOI 10.1002/jso.27996↗
  4. Trends and Outcomes of Neoadjuvant Chemotherapy for Clinical Stage T1 Pancreatic Cancer. Co-author DOI 10.1002/jso.28003↗
  5. Impact of Environmental Quality on Pancreatic Cancer Outcomes Post Pancreatoduodenectomy: A Retrospective Cohort Study. Co-author DOI 10.1007/s12029-025-01254-4↗
  6. Standard-Adherent Surgery and Guideline-Based Therapy in Pancreatic Cancer: A Multicenter Analysis. Co-author DOI 10.1245/s10434-025-17467-7↗
  7. Management of Peritoneal Metastasis in Patients with Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/curroncol32020103↗
  8. Outcomes of minimally invasive vs. open pancreatoduodenectomies in pancreatic adenocarcinoma: analysis of ACS-NSQIP data. Co-author DOI 10.1007/s00423-024-03454-1↗
  9. Modified 5-Item Frailty Index (mFI-5) may predict postoperative outcomes after pancreatoduodenectomy for pancreatic Cancer. Co-author DOI 10.1007/s00423-024-03483-w↗
  10. Factors Influencing Immunotherapy Utilization in Stage IV Pancreatic Cancer: Impact of Race and Socioeconomics in the U.S. Co-author DOI 10.1007/s12029-024-01119-2↗
  11. Comparison of neoadjuvant chemotherapy plus radiation vs. chemotherapy alone on complete pathologic response in pancreatic adenocarcinoma: an analysis of the n… Last author DOI 10.1007/s44337-024-00145-0↗
  12. Minorities Face Delays to Pancreatic Cancer Treatment Regardless of Diagnosis Setting. Co-author DOI 10.1245/s10434-024-15352-3↗
  13. ASO Author Reflections: Identifying and Understanding How Vulnerable Populations Are Affected by Delays in Pancreatic Cancer Care. Co-author DOI 10.1245/s10434-024-15476-6↗
  14. Advance care planning in patients undergoing surgery to resect pancreatic adenocarcinoma: Underlying tension between balancing hope and realism. Last author DOI 10.1016/j.surg.2021.08.033↗
  15. Pancreatic Cancer Patient-derived Organoids Can Predict Response to Neoadjuvant Chemotherapy. Co-author DOI 10.1097/sla.0000000000005558↗
  16. The Impact of Socioeconomic Deprivation on Clinical Outcomes for Pancreatic Adenocarcinoma at a High-volume Cancer Center: A Retrospective Cohort Analysis. Co-author DOI 10.1097/sla.0000000000003706↗
  17. Cancer outcomes are independent of preoperative CA 19-9 in anatomically resectable pancreatic ductal adenocarcinoma: A retrospective cohort analysis. First author DOI 10.1002/jso.26103↗
  18. Completion of adjuvant therapy in patients with resected pancreatic cancer. Co-author DOI 10.1016/j.hpb.2019.07.008↗

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sepideh Gholami · 9 shared papers, 2024–2026 · strength 2.24
  2. Oliver J. Standring · 10 shared papers, 2022–2026 · strength 2.19
  3. Daniel A. King · 10 shared papers, 2022–2026 · strength 2.15
  4. Marcovalerio Melis · 7 shared papers, 2024–2026 · strength 1.70
  5. Elliot Newman · 7 shared papers, 2024–2026 · strength 1.70
  6. Abdullah Khalid · 7 shared papers, 2024–2026 · strength 1.70
  7. Lyudmyla Demyan · 8 shared papers, 2022–2025 · strength 1.54
  8. Matthew John Weiss · 7 shared papers, 2022–2025 · strength 1.54
  9. Shamsher Ali Pasha · 7 shared papers, 2022–2025 · strength 1.39
  10. Matthew John Weiss · 6 shared papers, 2022–2025 · strength 1.19
  11. Gary Deutsch · 6 shared papers, 2022–2025 · strength 1.11
  12. Joseph M. Herman · 5 shared papers, 2022–2024 · strength 0.85
  13. Neha L. Lad · 2 shared papers, 2024–2025 · strength 0.46
  14. Neda Amini · 2 shared papers, 2024–2025 · strength 0.46
  15. Grace Wu · 2 shared papers, 2022–2025 · strength 0.39
  16. John Fallon · 2 shared papers, 2024 · strength 0.38
  17. Benjamin Daniel Powers · 3 shared papers, 2020–2021 · strength 0.34
  18. Mokenge Peter Malafa · 3 shared papers, 2020–2021 · strength 0.34
  19. Jason B. Fleming · 3 shared papers, 2020–2021 · strength 0.34
  20. Pamela Joy Hodul · 3 shared papers, 2020–2021 · strength 0.34
  21. Matthew J. Weiss · 1 shared paper, 2026 · strength 0.32
  22. M. Weiss · 1 shared paper, 2026 · strength 0.30
  23. Gerardo A. Vitiello · 1 shared paper, 2026 · strength 0.30
  24. Julien T. Hohenleitner · 1 shared paper, 2026 · strength 0.30
  25. Shruti Koti · 1 shared paper, 2025 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.